Merck & Co., Inc. (NYSE:MRK) is on Jim Cramer’s radar, with shares up 1.9% year-to-date after a strong run since early November. The stock faced challenges earlier in the year, including halting Gardasil HPV vaccine shipments in China due to inventory buildup. Merck’s blockbuster drug Keytruda has been a top seller, but pressure remains to develop successors.

On November 18th, Merck & Co., Inc. (NYSE:MRK) announced success in a phase two trial for its Winrevair drug for pulmonary hypertension, leading to a phase three study. Bank of America raised the stock’s price target to $120, citing strong potential. Cramer believes Merck & Co., Inc. (NYSE:MRK) may be undervalued, calling it an inexpensive stock.

While Merck & Co., Inc. (NYSE:MRK) shows promise, some believe AI stocks offer higher returns and less downside risk. For those interested in an inexpensive AI stock benefiting from Trump tariffs and onshoring, a report on the best short-term AI stock is available.

Read more at Yahoo Finance: “Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer